Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexipiprazole adjunctive therapy in MDD
NCT01052077Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Brexipiprazole + ADT with Placebo + ADT (2 arms). Primary endpoint: Montgomery Asberg Depression Rating Scale Total Score at 14 weeks. Started Mar 2010; status: completed.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01052077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052077.